Healthcare | May 19, 2026
Zydus Wellness FY26 revenue climbs to Rs. 39.4 billion
Growth driven by strong performance across Sugar Free, RiteBite Max Protein, Everyuth, Glucon-D and Nutralite portfolios
Growth driven by strong performance across Sugar Free, RiteBite Max Protein, Everyuth, Glucon-D and Nutralite portfolios
Growth was driven by expansion across key business segments, improving efficiencies, and sustained demand across institutional and retail channels
This positions its platform as a rapidly evolving engine for next-generation genetic medicine
The CDMO segment saw a 22% decline in Q4 due to a strong base in the prior year
The once-daily oral therapy is the first and only tyrosine kinase 2 (TYK2) inhibitor approved in the European Union for this indication, marking a significant expansion of its immunology portfolio
Hair care & quick commerce shine
In Q4 FY26, the company reported revenue from operations of Rs 176.9 crore, marking a 23.6% year-on-year growth
Patients receiving ELREXFIO largely remained free from disease progression during the interim analysis
Growth was broad-based across segments
The investment will bring in cutting-edge downstream fermentation technology, strengthening the company’s contract manufacturing capabilities for drug substances
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
